Ranking Invest

Exact Sciences Corporation

Segmento: Healthcare Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Indicadores Básicos

Valor de Mercado

$ 8.72 Bi

IVR

-0.02

IVR2

-0.27

Índices de Previsibilidade

Faturamento

0.02

Lucro

0.46

Margem

1.45

Índices de Tendência

Faturamento

11.71

Lucro

10.05

Margem

10.97

Índices de Endividamento

DIV/PAT

0.91

DIV/L4T

-2.13

Dívida Líquida

$ 2.17 Bi

Patrimônio Líquido

$ 2.40 Bi

L4T

-$ 1.02 Bi

MM4T

-35.79%

Dívidas
Dividendos
Cotação: $45.68

Não há dados de histórico de dividendos para exibir.

Gráfico Lucro/Faturamento X Trimestre